Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients

Molecular Psychiatry

Volumn 5, Issue 3, 2000, Pages 293-300

  Takahashi, M ^a   Shirakawa, O ^b   Toyooka, K ^c   Kitamura, N ^d   Hashimoto, T ^e   Maeda, K ^b   Koizumi, S ^b   Wakabayashi, K ^f   Takahashi, H ^b   Someya, T ^c   Nawa, H ^a,b,f  

^a Molecular Neurobiology Brain Research Institute   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

^d KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Novartis Pharma   (Japan)

^f KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

BDNF; Calbindin D; Development; Haloperidol; Neurotrophin; Postmortem brain; TrkB

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALBINDIN; CHLORPROMAZINE; GROWTH FACTOR RECEPTOR; HALOPERIDOL; LEVOMEPROMAZINE; NERVE GROWTH FACTOR; NEUROLEPTIC AGENT; NEUROTROPHIN 3; OXYPERTINE; PERICIAZINE; THIORIDAZINE; TIOTIXENE; TRIMIPRAMINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CINGULATE GYRUS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; LIMBIC SYSTEM; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

EID: 0000754856     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000718     Document Type: Article

References (45)

1. Weinberger DR. Implication of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669.
2. Waddington JL. Schizophrenia: developmental neuroscience and pathobiology. Lancet 1993; 341: 531-536.
3. Stoop R, Poo MM. Synaptic modulation by neurotrophic factors. Prog Brain Res 1996; 109: 359-364.
4. Lewin GR, Barde YA. Physiology of the neurotrophins. Ann Rev Neurosci 199G; 19: 289-317.
5. Schuman EM. Neurotrophin regulation of synaptic transmission. Curr Opin Neurobiol 1999; 9: 105-109.
6. Jankowsky JL, Patterson PH. Cytokine and growth factor involvement in long term potentiation. Molec Cell Neurosci 1999; 14: 273-286.
7. Cabelli RJ, Hohn A, Shatz CJ. Inhibition of ocular dominance column formation by infusion of NT-4/5 or BDNF. Science 1995; 267: 1662-1666.
8. Prakash N, Cohen CS, Frostig RD. Rapid and opposite effects of BDNF and NGF on the functional organization of the adult cortex in vivo. Nature 1996; 381: 702-706.
9. Ringstedt T, Linnarsson S, Wagner J, Lendahl U, Kokaia Z, Arenas E et al. BDNF regulates reelin expression and Cajal-Retzius cell development in the cerebral cortex. Neuron 1998; 21: 305-315.
10. Nawa H, Pelleymounter MA, Carnahan J. Intraventricular administration of BDNF increases neuropeptide expression in neu-born rat brain. J Neurosci 1994; 14: 3751-3765.
11. Mizuno K, Carnahan J, Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994; 105: 243-256.
12. Ahmed S, Reynolds BA, Weiss S. BDNF enhances the differentiation but not the survival of CNS stem cell-derived neuronal precursors. J Neurosci 1995; 15: 5765-5778.
13. Takei N, Sasaoka K, Inoue K, Takahashi M, Endo Y, Hatanaka H. Brain-derived neurotrophic factor increases the stimulation-evoked release of glutamate and the levels of exocytosis-associated proteins in cultured cortical neurons from embryonic rats. / Neurochem 1997; 68: 370-375.
14. Marty S, Berninger B, Carroll P, Thoenen H. GABAergic stimulation regulates the phenotype of hippocampal interneurons through the regulation of brain-derived neurotrophic factor. Neuron 1996; 16: 565-570.
15. Narisawa-Saito M, Carnahan J, Araki K, Yamaguchi T, Nawa H. Brain-derived neurotrophic factor regulates the expression of AMPA receptor proteins in neocortical neurons. Neuroscience 1999; 88: 1009-1014.
16. Korsching S, Thoenen H. Two-site enzyme immunoassay for nerve growth factor. Meth Enzymol 1987; 147: 167-185.
17. Nawa H, Carnahan J, Gall C. BDNF protein measured by a novel enzyme immunoassay in normal brain and after seizure: partial disagreement with mRNA levels. Eur J Neurosci 1995; 7: 1527-1535.
18. Frank L, Ventimiglia R, Anderson K, Lindsay RM, Rudge JS. BDNF down-regulates neurotrophin responsiveness, TrkB protein and TrkB mRNA levels in cultured rat hippocampal neurons. Eur J Neurosci 1996; 8: 1220-1230.
19. Nieuwenhunhuys, R, Voogd J, van Huijzen CHR. The Human Central Nen-ous System-A Synopsis and Atlas. Springer-Verlag, Berlin, 1988.
20. Pappas IS, Parnavelas JG. Neurotrophins and basic fibroblast growth factor induce the differentiation of calbindin-containing neurons in the cerebral cortex. Exp Neural 1997; 144: 302-314.
21. Sokolov BP. Expression of NMDAR1, GluRl, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of 'neuroleptic-free' schizophrenics: evidence on reversible up-regulation by typical neuroleptics. / Neurochem 1998; 71: 2454-2464.
22. McAllistcr CG, van Kämmen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am }Psychiatry 1995; 152: 1291-1297.
23. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 1996; 7: 2925-2928.
24. Zafra F, Hengerer B, Leibrock J, Thoenen H, Lindholm D. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J 1990; 9: 3545-3550.
25. Bessho Y, Nakanishi S, Nawa H. Glutamate receptor agonists enhance the expression of BDNF mRNA in cultured cerebellar granule cells. Mol Brain Res 1993; 18: 201-208.
26. Tamminga CA, Thaker GK, Duchanan R, Kirkpatrick B, Alphs LD, Chase TN et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992; 49: 522-530.
27. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RSJ. Pattern of cerebral blood flou1 in schizophrenia. Br J Psychiatry 1982; 1GO: 179-186.
28. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
29. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; G: 869-872.
30. Castren E, da Penha Berzaghi M, Lindholm D, Thoenen H. Differential effects of MK-801 on brain-derived neurotrophic factor mRNA levels in different regions of the rat brain. Exp Neural 1993; 122: 244-252.
31. Harrison PJ, McLaughlin D, Kerwin RW. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 1991; 337: 450-452.
32. Eastwood SL, McDonald B, Burnet PW, Beckwith JP, Kerwin RW, Harrison PJ. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluRl and GluR2 in medial temporal lobe neurons in schizophrenia. Afo/ Brain fles 1995; 29: 211-223.
33. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995; 52: 258-266.
34. Eastwood SL, Burnet PW, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 1995; 66: 309-319.
35. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch Gen Psychiatry 1997; 54: 660-669.
36. Gabriel SM, Davidson M, Haroutunian V, Powchik P, Bierer LM, Purohit DP et al. Neuropeptide deficits in schizophrenia vs Alzheimer's disease cerebral cortex. Biol Psychiatry 1996; 39: 82-91.
37. Nemeroff CB, Youngblood WW, Manberg PJ, Prange AJ-Jr, Kizer JS. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science 1983; 221: 972-975.
38. Pesold C, Impagnatiello F, Pisu MG, Uzunov DP, Costa E, Guidotti A et al. Reelin is preferentially expressed in neurons synthesizing gamma-aminobutyric acid in cortex and hippocampus of adult rats. Proc Natl Acad Sci USA 1998; 95: 3221-3226.
39. Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 1998; 22: 15718-15723.
40. Arnold SE, Hyman BT, Van HG, Damasio AR. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 1991; 48: 625-632.
41. Conrad AJ, Abebe T, Austin R, Forsythe S, Scheibel AB. Hippocampal pyramidal cell disarray in schizophrenia as a bilateral phenomenon. Arch Gen Psychiatry 1991; 48: 413-417.
42. Akbarian S, Kim JJ, Potkin SG, Hetrick WP, Bunney WE Jr, Jones EG. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry 1996; 53: 425-136.
43. D'Arcangelo G, Miao GG, Chen SC, Soares HD, Morgan JI, Curran T. A protein related to extracellular matrix proteins deleted in the mouse mutant reeler. Nature 1995; 374: 719-723.
44. Del Rio JA, Heimrich B, Borrell V, Forster E, Drakew A, Alcantara S et al. A role for Cajal-Retzius cells and reelin in the development of hippocampal connections. Nature 1997; 385: 70-74. Reference added in proof
45. Chlan-Fourney J, Li X-M, Juorio AV, Ashe P, Boulton AA. Differential regulation of brain derived neurotrophic factor (BDNF) mRNA in rat brain by chronic haloperidol, risperidone and clozapine treat..rnent. Soc Neurosci Abs 1998; 24: 295.4.